Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers 

ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers 


Date: May 17, 2018

Breakfast: 5:15 AM
Scientific Session: 6:00 AM - 7:30 AM

Location:
Marriott Marquis
Marquis Ballroom 5
901 Massachusetts Avenue NW
Washington DC, 20001

Overview

The advent of PARP inhibitor therapy is transforming the treatment landscape for patients with breast and ovarian cancers. There is a substantial clinical need for educational activities targeted to nurses concerning these approaches because they are vastly different from conventional chemotherapeutic options, and because of the frequent and unique opportunities that nurses have to educate their patients and improve clinical outcomes. Given the important and ever-increasing role of nurses on the frontlines of cancer care and engagement with their patients, it is a clinical priority for oncology nurses to understand the effectiveness of these new strategies, some methods to mitigate and manage predictable and distinct adverse events, and the importance of counseling their patients concerning the use of these novel approaches, which are very different from traditional oncology agents regarding their germline-targeting, efficacy, and adverse-event characteristics.

Led by an expert panel composed of Physician and Nurse Co-Chairs, this PER Forum‒styled breakfast symposium at ONS 2018 will discuss best practices that oncology nurses can utilize in the treatment, management, and overall care of patients with breast and ovarian cancers who are undergoing treatment with PARP inhibitors. The interactive nature of this highly practical Forum’s educational format will encourage the sharing of evolving strategies and clinical skills, while fostering collaboration between the multidisciplinary faculty and advanced participants. Presentations will be concise and used to springboard into multidisciplinary discussions, cases, and extensive Q&A sessions, allowing the audience to discuss cases and scenarios from their own practices.

Target Audience

This educational program is directed toward all attendees of the ONS 43rd Annual Congress, including nurses and other healthcare professionals with an interest in the treatment of lung cancer.

Learning Objectives

Upon completion of this activity, participants should be better prepared to:

  • Outline the underlying mechanisms by which PARP inhibitors exert their activity in the treatment of cancer
  • Delineate key concepts and findings from pivotal trials that have evaluated PARP inhibitors for the treatment of ovarian and breast cancers
  • Practically apply knowledge of PARP inhibitor strategies to real-world clinical scenarios in which nurses counsel patients with ovarian and breast cancers
  • Develop processes to proactively mitigate the impact of adverse events in the treatment of ovarian and breast cancers

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Program Chair

Bradley J. Monk, MD, FACS, FACOG
Arizona Oncology (US Oncology Network)
Professor, Gynecologic Oncology: University of Arizona and Creighton University
Medical Director of US Oncology Research Gynecology Program
Phoenix, AZ
 

Lorraine M. Lopez, RN, BSN
Nurse Manager
Arizona Oncology – Biltmore Cancer Center
Division of Gynecology Oncology
Phoenix, AZ







Become a Member

Forgot Password?
Filter By